IDH2 mutation has been detected in 0.9% of anaplastic astrocytomas7 and noncanonical IDH1 mutations—although have not been associated with different prognostic values from the canonical ones—account for 7.9% of anaplastic gliomas.31Thus, in our cohort, we may have missed 3 cases with these mutations, if a respective analysis was conducted. Here, IDH2 is linked to grade III glioma.